Viatris defeats biogen's attempt to revive tecfidera patent

Federal circuit refuses to reconsider decision invalidating biogen's patent covering its multiple sclerosis product tecfidera® pittsburgh, march 17, 2022 /prnewswire/ -- viatris inc. (nasdaq: vtrs) today announced that it is pleased with the decision by the united states court of appeals for the federal circuit denying biogen's request that the court reconsider its prior decision affirming the invalidity of biogen's u.s. patent no. 8,399,514, covering tecfidera®.
VTRS Ratings Summary
VTRS Quant Ranking